Bottom Line Booster

Published on: 
, ,

Pharmaceutical Executive

Pharmaceutical Executive, Pharmaceutical Executive-07-01-2001, Volume 0, Issue 0

Given the colossal revenue generated by just one blockbuster drug, it's no surprise that R&D always finds its way to the top of management's agenda. But now more than ever, pharmaceutical companies can't thrive on discovery alone. Price pressure from the public and private sectors drives companies to create savings through operational efficiencies. One of the biggest areas for financial gain"better management of capital assets"is often overlooked.